Skip to main content
SpringerLink
Log in

Acute Kidney Injury and Liver Disease: Incidence, Pathophysiology, Prevention/Treatment, and Outcomes

  • Chapter
  • First Online:
Core Concepts in Acute Kidney Injury

  • 1599 Accesses

Abstract

Acute kidney injury (AKI) is common in patients with cirrhosis and is associated with significant morbidity and mortality. The pathophysiologic cascade triggered by the onset of portal hypertension results in chronic renal hypoperfusion and renders the kidneys unable to compensate in the face of secondary insults such as gastrointestinal bleeding and spontaneous bacterial peritonitis. The most common etiologies of AKI in this setting include prerenal azotemia, acute tubular necrosis (ATN), and hepatorenal syndrome (HRS). Recent consensus criteria have attempted to modernize the definition of AKI in cirrhosis by adopting a threshold of a rise in creatinine of 0.3 mg/dL or 50% from baseline and by eliminating a creatinine cutoff for the diagnosis of hepatorenal syndrome. Despite these standardized criteria, distinguishing between AKI etiologies remains difficult in patients with cirrhosis. Many of the traditional means of differential diagnosis, including measuring the fractional excretion of sodium and examining urine sediment, perform suboptimally in cirrhosis. Recent studies have identified multiple urinary biomarkers associated with structural kidney injury that have shown promise for the ability to distinguish ATN from HRS. Accurately making this distinction is critical as treatment with vasoconstrictors combined with albumin significantly improves renal function and reduced mortality in patients with HRS. The most widely studied vasoconstrictor, terlipressin, has been shown to reverse HRS which is approximately 50% of cases. Although terlipressin is unavailable in the United States, small studies suggest that norepinephrine (but not the combination of midodrine and octreotide) may be similarly efficacious.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48:2064–77.

    Article  CAS  PubMed  Google Scholar 

  2. Du Cheyron D, Bouchet B, Parienti JJ, et al. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med. 2005;31(12):1693–9.

    Article  PubMed  Google Scholar 

  3. Fang JT, Tsai MH, Tian YC, et al. Outcome predictors and new score of critically ill cirrhotic patients with acute renal failure. Nephrol Dial Transplant. 2008;23(6):1961–9.

    Article  PubMed  Google Scholar 

  4. Cholongitas E, Senzolo M, Patch D, et al. Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol. 2009;21(7):744–50.

    Article  PubMed  Google Scholar 

  5. Hsu CY, McCulloch CE, Fan D, et al. Community-based incidence of acute renal failure. Kidney Int. 2007;72(2):208–12.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest. 1999;104:1223–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41:422–33.

    Article  CAS  PubMed  Google Scholar 

  8. Martin PY, Ohara M, Gines P, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest. 1998;101:235–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lee FY, Colombato LA, Albillos A, et al. N omega-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension, and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology. 1993;17:84–90.

    Article  CAS  PubMed  Google Scholar 

  10. Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003;37:208–17.

    Article  CAS  PubMed  Google Scholar 

  11. Francés R, Zapater P, González Navajas JM, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology. 2008;47:978–85.

    Article  PubMed  Google Scholar 

  12. Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology. 2009;49:1245–56.

    Article  CAS  PubMed  Google Scholar 

  13. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151–7.

    Article  CAS  PubMed  Google Scholar 

  14. Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23:164–76.

    Article  CAS  PubMed  Google Scholar 

  15. Guevara M, Bru C, Ginès P, et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology. 1998;28:39–44.

    Article  CAS  PubMed  Google Scholar 

  16. Laffi G, La Villa G, Pinzani M, et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol. 1997;17:530–48.

    CAS  PubMed  Google Scholar 

  17. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439–47.

    Article  CAS  PubMed  Google Scholar 

  18. Krag A, Bendtsen F, Henriksen JH, et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105–10.

    Article  CAS  PubMed  Google Scholar 

  19. Nazar A, Guevara M, Sitges M, et al. Left ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol. 2013;58:51–7.

    Article  PubMed  Google Scholar 

  20. Belcher JM, Parikh CR, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol. 2013;11(12):1550–8.

    Article  CAS  PubMed  Google Scholar 

  21. Cupples WA, Braam B. Assessment of renal autoregulation. Am J Physiol Ren Physiol. 2007;292:F1105–23.

    Article  CAS  Google Scholar 

  22. Sansoé E, Silvano S, Mengozzi G, et al. Loss of tubuloglomerular feedback in decompensated liver cirrhosis: physiopathological implications. Dig Dis Sci. 2005;50:955–63.

    Article  PubMed  Google Scholar 

  23. Stadlbauer VP, Wright GAK, Banaji M, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology. 2008;134:111–9.

    Article  PubMed  Google Scholar 

  24. Bories PN, Campillo B, Azaou L, et al. Long-lasting NO overproduction in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1997;25:1328–33.

    Article  CAS  PubMed  Google Scholar 

  25. Grangé JD, Amiot X. Nitric oxide and renal function in cirrhotic patients with ascites: from pathophysiology to practice. Eur J Gastroenterol Hepatol. 2004;16:567–70.

    Article  PubMed  Google Scholar 

  26. Davenport A. Difficulties in assessing renal function in patients with cirrhosis: potential impact on patient treatment. Intensive Care Med. 2011;37:930–2.

    Article  PubMed  Google Scholar 

  27. Salerno F, Gines A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Wong F, Nadim MK, Kellum JA, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011;60:702–9.

    Article  PubMed  Google Scholar 

  29. Angeli P, Gatta A, Caregaro L, et al. Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. Eur J Clin Investig. 1990;20:111–7.

    Article  CAS  Google Scholar 

  30. Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62:131–7.

    Article  PubMed  Google Scholar 

  31. Wong F, O’Leary JG, Reddy KR, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology. 2013;145(6):1280–8.

    Article  PubMed  Google Scholar 

  32. Arroyo V. Acute kidney injury (AKI) in cirrhosis: should we change current definition and diagnostic criteria of renal failure in cirrhosis? J Hepatol. 2013;59:415–7.

    Article  PubMed  Google Scholar 

  33. Cardenas A. Defining renal failure in cirrhosis—acute kidney injury classification or traditional criteria? Ann Hepatol. 2013;12:984–5.

    PubMed  Google Scholar 

  34. Piano S, Rosi S, Maresio G, et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol. 2013;59:482–9.

    Article  PubMed  Google Scholar 

  35. Fagundes C, Barreto R, Guevara M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol. 2013;59:474–81.

    Article  PubMed  Google Scholar 

  36. Ferreira CN, Rodrigues T, Cortez-Pinto H, et al. The new definition of acute kidney injury in patients with cirrhosis: a critical look. Gut. 2012;61:1513.

    Article  Google Scholar 

  37. Newsome BB, Warnock DG, McClellan WM, et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med. 2008;168:609–16.

    Article  CAS  PubMed  Google Scholar 

  38. Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2013;57(2):753–62.

    Article  CAS  PubMed  Google Scholar 

  39. Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531–7.

    Article  CAS  PubMed  Google Scholar 

  40. Wong F, et al. Reduction in acute kidney injury (AKI) is a strong predictor of survival in patients with hepatorenal syndrome type-1 (HRS-1) treated with terlipressin plus albumin or albumin alone. Nephrol Dial Transplant. 2015;30:Siii451.

    Article  Google Scholar 

  41. Scott RA, Austin AS, Kolhe NV, et al. Acute kidney injury is independently associated with death in patients with cirrhosis. Frontline Gastroenterol. 2013;4:191–7.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Martin-Llahi M, Guevara M, Torre A, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology. 2011;140:488–96.

    Article  PubMed  Google Scholar 

  43. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–36.

    Article  CAS  PubMed  Google Scholar 

  44. Wong F, Leung W, Beshir M, et al. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transpl. 2015;21(3):300–7.

    Article  PubMed  Google Scholar 

  45. Magri P, Auletta M, Andreucci M, et al. Sodium retention in preascitic stage of cirrhosis. Semin Nephrol. 2001;21(3):317–22.

    Article  CAS  PubMed  Google Scholar 

  46. Diamond JR, Yoburn DC. Nonoligouric acute renal failure associated with a low fractional excretion of sodium. Ann Intern Med. 1982;96(5):597–600.

    Article  CAS  PubMed  Google Scholar 

  47. Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med. 2007;357(8):797–805.

    Article  CAS  PubMed  Google Scholar 

  48. Verna EC, Brown RS, Farrand E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci. 2012;57(9):2362–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Belcher JM, Edelstein CL, Parikh CR. Clinical applications of biomarkers for acute kidney injury. Am J Kidney Dis. 2011;57(6):930–40.

    Article  PubMed  Google Scholar 

  50. Fagundes C, Pepin MN, Guevara M, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol. 2012;57(2):267–73.

    Article  CAS  PubMed  Google Scholar 

  51. Qasem AA, Farag SE, Hamed E, et al. Urinary biomarkers of acute kidney injury in patients with cirrhosis. ISRN Nephrol. 2014:376795. https://doi.org/10.1155/2014/376795.

    Article  Google Scholar 

  52. Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60(2):622–32.

    Article  CAS  PubMed  Google Scholar 

  53. Ariza X, Solà E, Elia C, et al. Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis. PLoS One. 2015;10(6):e0128145.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Cavallin M, Fasolato S, Marenco S, et al. The treatment of hepatorenal syndrome. Dig Dis. 2015;33(4):548–54.

    Article  PubMed  Google Scholar 

  55. Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150(7):1579–89.

    Article  CAS  PubMed  Google Scholar 

  56. Sanyal AJ, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomized clinical studies. Aliment Pharmacol Ther. 2017;45(11):1390–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion verses intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016;63:983–92.

    Article  CAS  PubMed  Google Scholar 

  58. Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51(1):219–26.

    Article  CAS  PubMed  Google Scholar 

  59. Sharma P, Kumar A, Sharma BC, et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103(7):1689–97.

    Article  CAS  PubMed  Google Scholar 

  60. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55(2):315–21.

    Article  CAS  PubMed  Google Scholar 

  61. Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015;62(2):567–74.

    Article  CAS  PubMed  Google Scholar 

  62. de Mattos AZ, de Mattos AA, Ribeiro RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol. 2016;28:345–51.

    Article  PubMed  Google Scholar 

  63. Srivastava S, Shalimar, Vishnubhatla S, et al. Randomized controlled trial comparing the efficacy of Terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome. J Clin Exp Hepatol. 2015;5(4):276–85.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Guevara M, Ginès P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. J Hepatol. 1998;28(2):416–22.

    Article  CAS  Google Scholar 

  65. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47:288–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Bai M, Qi XS, Yang ZP, et al. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol. 2014;20(10):2704–14.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Capling RK, Bastani B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail. 2004;26:563–8.

    Article  PubMed  Google Scholar 

  68. Keller F, Heinze H, Jochimsen F, et al. Risk factors and outcomes of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail. 1995;17:135–46.

    Article  CAS  PubMed  Google Scholar 

  69. Wong LP, Blackley MP, Andreoni KA, et al. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int. 2005;68:362–70.

    Article  PubMed  Google Scholar 

  70. Zhang Z, Maddukuri G, Jaipail N, et al. Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor therapy and albumin. J Crit Care. 2015;30(5):969–74.

    Article  CAS  PubMed  Google Scholar 

  71. Wlodzimirow KA, Eslami S, Abu-Hanna A, et al. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int. 2013;33:40–52.

    Article  PubMed  Google Scholar 

  72. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif. 2002;20:252–61.

    Article  PubMed  Google Scholar 

  73. Sarin S, Kumar A, Almeida JA, et al. Acute-on-chronic-liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3(1):269–82.

    Article  PubMed  Google Scholar 

  74. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–37.

    Article  PubMed  Google Scholar 

  75. Jalan R, Yurdaydin C, Bajaj JS, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. 2014;147:4–10.

    Article  PubMed  Google Scholar 

  76. Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038–47.

    Article  PubMed  Google Scholar 

  77. Bajaj JS, O’Learey JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology. 2014;60(1):250–6.

    Article  PubMed  Google Scholar 

  78. Bernal W, Jalan R, Quaglia A, et al. Acute-on-chronic liver failure. Lancet. 2015;386(10003):1576–87.

    Article  PubMed  Google Scholar 

  79. Moreau R, Arroyo A. Acute-on-chronic liver failure: a new clinical entity. Clin Gastroenterol Hepatol. 2015;13(5):836–41.

    Article  PubMed  Google Scholar 

  80. Garg H, Kumar A, Garg V, et al. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis. 2012;44(2):166–71.

    Article  PubMed  Google Scholar 

  81. Jindal A, Sarin SK, et al. Acute kidney injury (AKI) at admission and its response to terlipressin as a predictor of mortality in patients with acute-on-chronic liver failure (ACLF). J Hepatol. 2013;58(Suppl 1):S89.

    Article  Google Scholar 

  82. Maiwall R, Kumar S, Vashishtha C, et al. Acute kidney injury (AKI) in patients with acute on chronic liver failure (ACLF) is different from patients with cirrhosis. Hepatology. 2012;58(4 Suppl):36A–91A.

    Google Scholar 

  83. Angeli P, Rodríguez E, Piano S, et al. Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. Gut. 2015;64(10):1616–22.

    Article  PubMed  Google Scholar 

  84. Ariza X, Graupera I, Coll M, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J Hepatol. 2016;65:57. https://doi.org/10.1016/j.jhep.2016.03.002

    Article  CAS  PubMed  Google Scholar 

  85. Jalan R, Gines P, Olson JC, et al. Acute-on chronic liver failure. J Hepatol. 2012;57(6):1336–48.

    Article  PubMed  Google Scholar 

  86. Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818–24.

    Article  CAS  PubMed  Google Scholar 

  87. Shah N, El Zahraa Dhar D, Mohammed F, et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. J Hepatol. 2012;56:1047–53.

    Article  CAS  PubMed  Google Scholar 

  88. Parker R, Armstrong MJ, Corbett C, et al. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther. 2013;37(9):845–54.

    Article  CAS  PubMed  Google Scholar 

  89. Sidhu SS, Goyal O, Singla M, et al. Pentoxifylline in severe alcoholic hepatitis: a prospective, randomized trial. J Assoc Physicians India. 2012;60:20–2.

    PubMed  Google Scholar 

  90. Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1781–9.

    Article  CAS  PubMed  Google Scholar 

  91. Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology. 2010;138:1755–62.

    Article  CAS  PubMed  Google Scholar 

  92. Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372:1619–28.

    Article  CAS  PubMed  Google Scholar 

  93. Duan XZ, Liu FF, Tong JJ, et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol. 2013;19(7):1104–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012;142(3):505–12.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA

    Justin M. Belcher & Chirag R. Parikh

Authors
  1. Justin M. Belcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chirag R. Parikh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chirag R. Parikh .

Editor information

Editors and Affiliations

  1. Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Sushrut S. Waikar

  2. University College Dublin, Dublin, Ireland

    Patrick T. Murray

  3. Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Ajay K. Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Belcher, J.M., Parikh, C.R. (2018). Acute Kidney Injury and Liver Disease: Incidence, Pathophysiology, Prevention/Treatment, and Outcomes. In: Waikar, S., Murray, P., Singh, A. (eds) Core Concepts in Acute Kidney Injury. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-8628-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-8628-6_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-8626-2

  • Online ISBN: 978-1-4939-8628-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation